Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Highlights of this issue

Highlights of this issue

CMAJ September 16, 2003 169 (6) 537;
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Treating Alzheimer's disease with cholinesterase inhibitors

Figure

Figure. Photo by: Vincenzo Pietropaolo

Cholinesterase inhibitors are the mainstay of treatment for Alzheimer's disease and are recommended as such by the Canadian Consensus Conference on Dementia, however, it has been difficult to quantify the overall benefits and harms of these drugs. Lanctôt and colleagues review the efficacy and safety of the second-generation cholinesterase inhibitors donepezil, galantamine and rivastigmine that are currently marketed in Canada for the treatment of Alzheimer's disease. These drugs have been developed in an attempt to address the problems of short duration of action and lack of acetylcholinesterase specificity found in the original cholinesterase inhibitors. Using meta-analysis, the authors found that the number needed to treat to obtain a global response to cholinesterase inhibitors in a non-Asian population was 12, and 4 in a Japanese study. The number needed to harm 1 additional patient was found to be 12, although the authors note that the adverse events were largely gastrointestinal and that no drug-related deaths were reported. They conclude that the newer cholinesterase inhibitors are safe and that the current recommendations for the treatment of Alzheimer's disease are supported by the existing literature.

See page 557

Preventing violence against women

The Canadian Task Force on Preventive Health Care has reviewed the evidence regarding the potential benefits and harms of screening all women to detect abuse, interventions for abused women and treatment programs for men who abuse their partners. The Task Force concludes that based on the existing literature there is insufficient evidence to warrant routine screening. Four types of intervention for abused women were evaluated: shelters, post-shelter advocacy counselling, personal and vocational counselling, and prenatal counselling. The Task Force found evidence that women who had stayed 1 night in a shelter and had received a program of advocacy services reported less abuse and better quality of life over the ensuing 2 years than women who had only stayed in a shelter. Its review of the evidence for the value of programs that target male batterers yielded inconclusive results. Given the general lack of good evidence in this field, the Task Force concludes that there is a clear and pressing need for additional research to identify effective interventions to help women who suffer from domestic abuse.

See pages 570 and 582

Reducing inappropriate prescribing in primary care

Efforts to treat multiple medical problems in elderly patients, although well intentioned, can nevertheless contribute to increasing morbidity and mortality in this population. Clinicians are aware that drug interactions can be harmful, however, the sheer number of drugs available makes keeping track of all of their potential interactions impossible. Tamblyn and colleagues show that the use of specialized computer software in the physician's office can help reduce inappropriate prescribing. Interestingly, physicians who used the software were reluctant to stop existing therapies despite being warned of potential problems, and prescriptions deemed to be inappropriate were not eliminated.

See page 549

Hyperprolactinemia

Figure

Figure. Photo by: Myra Rudakewich

Serri and colleagues present a comprehensive and practical review of hyperprolactinemia. They include a description of the normal physiology of prolactin secretion and provide concise points to help clinicians recognize and diagnose states of prolactin excess. The authors summarize the objectives of treatment, including the management of this condition during pregnancy. Dopamine agonists are the usual medical therapy, but surgical options exist. Indications for surgery and a description of its relative effectiveness are also presented.

See page 575

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (6)
CMAJ
Vol. 169, Issue 6
16 Sep 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of this issue
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of this issue
CMAJ Sep 2003, 169 (6) 537;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Highlights of this issue
CMAJ Sep 2003, 169 (6) 537;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Treating Alzheimer's disease with cholinesterase inhibitors
    • Preventing violence against women
    • Reducing inappropriate prescribing in primary care
    • Hyperprolactinemia
  • Responses
  • Metrics
  • PDF

Related Articles

  • Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
  • Violence against women: integrating the evidence into clinical practice
  • Prevention of violence against women: Recommendation statement from the Canadian Task Force on Preventive Health Care
  • The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care
  • Diagnosis and management of hyperprolactinemia
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Highlights
  • Highlights
  • Highlights of this issue
Show more Highlights of this Issue

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire